Seek Returns

EXEL vs. RVTY: Exelixis vs. Revvity Stock Comparison

How do Exelixis (EXEL) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Exelixis (EXEL) and Revvity (RVTY)
Profile ItemEXELRVTY
NameExelixis Inc.Revvity Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization16.98 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateApril 17, 2000February 21, 1973
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

EXEL
RVTY
GSPC
Loading price history…
Exelixis (EXEL) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Exelixis (EXEL) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Exelixis (EXEL) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
Total Return (1Y)74.98%76.75%
Total Return (3Y, Annualized)50.33%24.22%
Total Return (5Y, Annualized)31.10%-1.48%

Risk Profile

Drawdown History

EXEL
RVTY
GSPC
Loading price history…
Exelixis (EXEL) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Exelixis (EXEL) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
Volatility (1Y, Annualized)34.17%40.22%
Beta (5Y)0.411.07
Max Drawdown (5Y)-35.41%-59.01%
Avg. Volume (3M)2.33M1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
EXEL and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
Sharpe Ratio (1Y)2.071.80
Sortino Ratio (1Y)3.232.90

Profitability

ROE (TTM)

Exelixis (EXEL) at 44.32% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for EXEL.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Exelixis (EXEL) at 40.75% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
ROE (TTM)44.32%3.45%
ROA (TTM)23.52%2.54%
Net Margin (TTM)35.45%8.61%
Operating Margin (TTM)40.75%17.06%
Gross Margin (TTM)96.26%55.91%

Growth

Revenue Growth

Both Exelixis (EXEL) at 6.98% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Exelixis (EXEL) at 57.95% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
Revenue Growth (YoY)6.98%3.67%
Revenue Growth (3Y CAGR)12.93%-4.82%
EPS Growth (YoY)57.95%-5.91%
EPS Growth (3Y CAGR)70.59%-23.26%

Financial Strength

Current Ratio (MRQ)

Both Exelixis (EXEL) at 3.21 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Exelixis (EXEL) at 0.09 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
Current Ratio (MRQ)3.212.65
Debt / Equity (MRQ)0.090.38
Net Debt / EBITDA-0.712.43

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
Dividend Yield (TTM)0.00%0.19%
Dividend Payout Ratio (TTM)0.00%13.40%

Valuation

P/E Ratio (TTM)

Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Exelixis (EXEL) at 6.80 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Revvity (RVTY) at 2.39 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
Exelixis (EXEL) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Revvity (RVTY)
MetricEXELRVTY
P/E Ratio (TTM)20.8368.94
P/S Ratio (TTM)6.805.88
P/B Ratio (MRQ)9.282.39
Free Cash Flow Yield (TTM)4.47%3.62%